Introduction
Metastatic renal cell carcinoma (mRCC) has historically been treated with cytokine therapy [1] . Though resection of the primary tumor in the setting of distant metastatic disease was felt to play both a diagnostic and a potentially therapeutic role in the management of mRCC, this approach has not been without controversy [2, 3] . However, in 2001, two prospective, randomized trials (SWOG 8949 and EORTC 30947) demonstrated that use of cytoreductive nephrectomy (CyNx) in patients with mRCC treated with interferon-alpha 2b improved overall survival, establishing CyNx as a treatment standard [4, 5] . A pooled analysis of both of these trials reported a median survival of 13.6 months for nephrectomy plus interferon versus 7.8 months for interferon alone. CyNx was associated with a 31 % decrease in the risk of death (p = 0.002).
The use of CyNx had been steadily increasing after 2001, and was generally viewed as a treatment standard for surgical candidates, particularly without extensive metastatic disease burden [6] . However, with the Food and Drug Administration (FDA) approval of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFRTKIs) in 2005, a shift in the standard systemic therapy for mRCC created an ''evidence void'' regarding the utility of CyNx. The appropriateness of extrapolating the results of SWOG 8949 and EORTC 30947, to the era of VEGFRTKIs, is unclear leaving clinicians uncertain of the appropriate role of CyNx. Given this recent change in existing level 1 evidence, it is important to examine ongoing changes in the patterns of modern day practice, as well as explore factors associated with the use of this treatment modality.
Material and methods

Patient cohort
Data for the current analysis were derived from the Surveillance, Epidemiology, and End Results (SEER) registry, which has collected clinical and pathological data on all incident cancer cases in specified geographic areas of the United States (US) since 1973, and are highly representative of the demographic makeup of the United States in terms of geography, socioeconomic status, race/ethnicity, and age. The 19 areas comprising the SEER registry represent approximately 26 % of the American population.
We identified patients diagnosed with histologically confirmed metastatic renal cell carcinoma (defined by confirmed metastases, local organ extension, or positive regional lymph nodes) diagnosed between years 2001 and 2008. Patients' baseline demographic data, year of surgery, and tumor characteristics were collected. The size of the primary tumor was clinically assessed based on radiographic imaging or pathologic specimens. CyNx was defined as surgical removal of a primary kidney tumor in the setting of mRCC. Patients who underwent radical nephrectomy, complete/total/simple nephrectomy, partial/ subtotal nephrectomy, or kidney resection with other organ resection were included in the CyNx group. Only patients who did not undergo surgery were included in the ''no surgery group.'' Patients who had unknown surgical procedures, not otherwise specified procedures, or surgery on regional and/or distant sites only were excluded from the analysis. We selected 2001 as the initial year for analysis to coincide with publication of SWOG 8949 and EORTC 30947 and 2005 as the time of initial regulatory approval for VEGFR-TKI's use in renal carcinoma [4, 5] . We 
Statistical analyses
The baseline differences in demographic characteristics of patients treated with and without CyNx were compared using the v 2 and t test for categorical and continuous variables, respectively. The trend in prevalence rates of CyNx over time was then analyzed using a modified poisson regression model with linear, quadratic, and cubic terms for time. The highest order term that was significant was the cubic term for time so that term and both lower order terms were retained in the final model, and a 3 df test for overall trend was computed. A multivariate modified Poisson regression model was utilized to estimate prevalence ratios to assess whether the VEGFR-TKI era, and other factors were independently associated with CyNx use. Because tumor size was missing for 436 patients, only 2012 of 2448 cases were included in the final adjusted analysis. Models were run both with and without adjustment for tumor size, and each of the prevalence ratios and their corresponding standard errors for any of the other covariates in the model were not changed with statistical significance. All analyses were performed using the Statistical Analysis Software (SAS) program, version 9.2 (SAS Institute, Cary, NC) and Statistical Package for the Social Sciences (SPSS), version 19 (IBM, Armonk, NY).
Results
The baseline patient characteristics are detailed in Table 1 
Discussion
The shift in the first-line treatment paradigm for metastatic RCC, from cytokines to VEGFR-TKIs, has resulted in an ''evidence void'' regarding the role of CyNx. In a previous study using the National Cancer Database (NCDB), a hospital-based cancer registry jointly sponsored by the American College of Surgeons and the American Cancer Society which represents over 75 % of all new cancer diagnoses in the United States, we found that the use of CyNx in patients with metastatic RCC has been decreasing since the FDA approval of VEGFR-TKIs in 2005 [7] . In addition, we identified several socioeconomic factors potentially associated with decreased application of CyNx. However, our prior study was limited in that only aggregate patient data were available, precluding multivariate analysis to determine which of several seemingly related variables were independently associated with a lower likelihood of undergoing CyNx. In the current analysis, with individual patient level data from SEER, we have confirmed and expanded our prior findings.
The current analysis reveals that the application of CyNx has declined since the approval of VEGFR-TKIs. This trend is not surprising, given the uncertainty regarding the utility of CyNx in the age of VEGFR-TKIs, and concerns for potentially delaying effective systemic therapy [8] . Two ongoing randomized phase III studies are expected to generate definitive evidence to guide the optimal use and timing of CyNx in the setting of newer generation systemic therapies [9] . CARMENA (NCT00930033) is a randomized phase III study comparing CyNx plus sunitinib to treatment with sunitinib alone in patients with mRCC with a primary endpoint of overall survival. A randomized phase III conducted by the European Organization of Research and Treatment of Cancer (NCT01099423) is comparing immediate versus deferred CyNx in patients with mRCC with a primary endpoint of progression-free survival. These trials are expected to be completed in 2013 and 2014, respectively. In addition to differences in the application of CyNx based on the 'era' of treatment, the current analysis also suggests that patient demographics were associated with the use of CyNx. Increasing age was associated with a decreased likelihood of CyNx. This finding was not unexpected, given concerns for increased operative morbidity and mortality in the elderly, particularly in the setting of an incurable malignancy [10] . Perhaps more concerning were the potential differences observed based on race, ethnicity, and marital status. Black and Hispanic patients were significantly less likely to undergo CyNx compared with Caucasians. While underlying biology of the disease may play a role [11, 12] , decreased accessibility and/or acceptability of CyNx is likely a more plausible explanation. Several studies have demonstrated decreased accessibility, and/or acceptability, of a variety of therapeutic modalities in racial/ethnic minority populations with other solid tumors [13, 14] . Martial status was also shown to be independently associated with undergoing CyNx in the current analysis, with married patients 59 % more likely to undergo surgery. Marital status has been regarded as an important surrogate for social support [15] , and previous studies have also described an association between marital status and the likelihood of undergoing CyNx [16, 17] .
Another interesting finding is that patients with larger tumors actually had increased odds of undergoing CyNx by 0.4 % per additional millimeter of tumor size. While speculative, this may be a result of an increased likelihood of symptoms associated with larger primary tumors, or at least the threat of impending morbidity, resulting in increased acceptance of CyNx by both the patient and urologist.
The current analysis has several potential strengths. SEER represents 18-26 % of the cancer population in the United States. Geographic regions included in SEER encompass varying levels of urbanization, income strata and education, mirroring the diversity of the greater United States population. Furthermore, the years encompassed by the SEER data include the time period when randomized trials both established the utility of CyNx and subsequently altered the systemic therapy landscape for renal carcinoma.
There are also several important limitations to the current analysis. First, and foremost, details regarding the specific systemic therapies administered were not available, and instead, we categorized cytokine and VEGFR-TKI eras based on the timing of initial regulatory approval of the VEGFR-TKIs. Second, data regarding co-morbidities and performance status were not ascertained, potential confounding factors regarding the use of cytoreductive nephrectomy. Third, limited by the data available in our study using the SEER database, the VEGF-TKI era is limited to years 2006-2008, and factors such as histological subtype, prognostic scores, treatment type, and length of treatment were not available for the analysis. Fourth, SEER data are limited to the United States, and the racial and socioeconomic disparities that were observed in the current analysis may not exist in other countries.
The role of CyNx in the management of mRCC in the VEGFR-TKI era is in evolution. Despite the lack of level 1 evidence, many still consider CyNx the default standard approach in appropriate surgical candidates, given the both diagnostic, and potential therapeutic, role of this treatment modality. Several retrospective studies have explored the role of CyNx in the VEGFR-TKI era and have suggested that the surgery is safe and may be associated with improved clinical outcomes [8, [18] [19] [20] [21] [22] [23] . To our knowledge, our study is the first to evaluate changes in the patterns of use of this modality in the cytokine versus VEGFR-TKI eras and supports the suspected general uncertainty regarding the appropriate integration of surgery in the age of targeted therapeutics. While we also identified potential racial, ethnic, and socioeconomic differences in the application of CyNx, the lack of a definitive role for CyNx in the current era limits the extent to which these differences can be considered inappropriate. Nonetheless, systematic differences in the application of a therapeutic modality for the treatment of cancer based on such factors remain concerning. The results of ongoing randomized trials evaluating the role of CyNx in the VEGFR-TKI era are awaited in an effort to optimize use of this treatment modality and to address barriers to accessibility and acceptability should CyNx be proven beneficial.
